My flu shot this past October had an estimated efficacy somewhere around 40%. I know this because I actually looked it up instead of assuming the thing in my arm was doing full work. 40% is not a great return on a needle stick. I accepted that ROI because the downside of going unprotected is worse. But the whole time I was thinking: the mRNA stack could fix this. The mRNA platform updates faster than conventional egg-based manufacturing. It can be reformulated in weeks rather than months. That is the entire upside. And now federal funding for mRNA flu vaccine research is being pulled before that upside has been realized.
This is not a close call for me. Canceling this research is a bad trade with asymmetric downside.
The Current Flu Shot Is a Known Underperformer
Conventional flu vaccines are manufactured in chicken eggs, a process that dates to the 1940s and introduces mutations that reduce how well the final product matches the circulating strain. Efficacy ranges from roughly 19% to 60% depending on the season and strain match. That variance is enormous. An investor would fire a fund manager for that kind of spread. We have accepted it in public health because the alternative, no vaccine, is worse.
mRNA changes the constraint that created this problem. The platform does not require eggs, does not require months of lead time for strain selection, and can be reformulated when surveillance data shows a mismatch developing mid-season. Moderna and Pfizer had mRNA flu candidates in clinical trials as recently as 2025, showing efficacy signals competitive with conventional vaccines and, in some early data, superior antibody breadth against mismatched strains. That work does not continue on its own. It needs sustained funding and regulatory support.
I will grant the critics one point: mRNA flu vaccines have not yet crossed the finish line. The Phase 3 data is not fully in. A reasonable person could argue we should not fund speculative platforms when existing vaccines are good enough. That argument is wrong, but it is not insane.
It is wrong because "good enough" is doing a lot of work in that sentence. Good enough relative to nothing. Not good enough relative to what the platform could deliver. And the next pandemic-scale influenza strain, when it comes, will not wait for us to restart a research program we mothballed for budget reasons.
What We Are Actually Paying For Is Optionality
Think about this as a portfolio decision. You do not buy insurance after the house burns down. mRNA flu research is not spending money on a luxury upgrade. It is maintaining the manufacturing and scientific infrastructure that allows rapid response. The COVID-19 mRNA vaccines went from sequence to first human dose in 63 days partly because the platform had been in development for years before SARS-CoV-2 appeared. Kill the flu program now and you shrink the institutional knowledge base, disperse the research teams, and lose years of compounding progress on delivery systems and adjuvant protocols.
My HRV and glucose data tell me nothing about pandemic preparedness. I know that. But the optimization logic is identical: small consistent investments in the platform produce outsized returns when you actually need it. Letting that infrastructure atrophy to save money in 2026 is like skipping your zone 2 cardio because you feel fine today.
The NIH and HHS need to reverse this. Not eventually. Before the teams dissolve and the trials stall permanently. The flu virus mutates on its own schedule, not ours.
